Drugs / PBK_L2201
last change Nov 2025 re-read 3 minutes ago

PBK_L2201

Developed for
osteoporosis
Investigated by
Pharmbio Korea Co., Ltd.

Trials 1

20252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT06154187 Feb 2024 → May 2025 osteoporosis Pharmbio Korea Co., Ltd. Unknown No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as PBK_L2201 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06154187 ↗